glp 1 peptide benefits GLP-1 Injections for Medical Weight Loss in Shoreline WA Peptides vs GLP-1: What's the

May 31-June 3, 2023

Vitamin B12 Pills vs Capsules vs Injections Vitamin B12 supplements can be divided into two main groups: Injections Oral supplements (capsules, tablets, drops, spray) Injections In regular cases, oral supplements are completely sufficient

Sequential start protocol (adding cagrilintide later) When to use: Already on semaglutide 2.4mg Plateaued on semaglutide alone Want to attribute side effects clearly More conservative approach Phase 1: Semaglutide foundation (weeks 1-20) Standard semaglutide titration to 2.4mg Weeks 1-4: 0.25mg Weeks 5-8: 0.5mg Weeks 9-12: 1.0mg Weeks 13-16: 1.7mg Week 17-20: 2.4mg (stabilize for 4 weeks) Phase 2: Add cagrilintide (week 21 onward) Continue semaglutide 2.4mg weekly Week 21-24: Add cagrilintide 0.6mg weekly Week 25-28: Increase to 1.2mg weekly Week 29-32: Increase to 1.8mg weekly Week 33+: 2.4mg weekly (both at maximum) Sequential protocol comparison: Benefits of sequential: Already accustomed to semaglutide effects Can clearly identify cagrilintide-specific side effects Option to stop cagrilintide if intolerable (keep semaglutide) Less overwhelming overall Good for plateaued semaglutide users Expected additional weight loss: On semaglutide 2.4mg alone: Lost 10-15% already After adding cagrilintide: Additional 5-10% over next 6-12 months Total: 15-25% combined Conservative dosing approach (lower maximum) For GI-sensitive individuals: Reduced target doses: Semaglutide: 1.7-2.0mg weekly (instead of 2.4mg) Cagrilintide: 1.8-2.0mg weekly (instead of 2.4mg) Same titration schedule, lower endpoint Better tolerability Extended titration (20+ weeks to maximum): Stay at each dose level 6 weeks instead of 4 Weeks 1-6: Starting doses Weeks 7-12: First increase Weeks 13-18: Second increase Weeks 19-24: Third increase Week 25+: Target doses Conservative protocol table: When to choose conservative: History of severe nausea on GLP-1s Older age (60+) Multiple medications Concerns about tolerability Budget constraints Don't need maximum possible weight loss Use SeekPeptides to design your personalized CagriSema protocol based on GI tolerance

In the UK, clinicians and patients can report suspected adverse drug reactions via the MHRA Yellow Card scheme (online/app/clinical systems)